Gilead Sciences Announces First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Gilead Sciences (GILD) PT Raised to $76 at BMO Capital Following 1Q
May 3, 2017 9:17 AM EDTBMO Capital raised its price target on Gilead Sciences (NASDAQ: GILD) to $76.00 (from $75.00) while maintaining a Market Perform rating. GILD reported 1Q revenues of $6.5bn, below the Street's estimates of $6.62bn, as continued strength from HIV could not off-set further deterioration in HCV.
GILD... More
Gilead Sciences (GILD) Misses Q1 EPS by 5c; Reiterates Full Year 2017 Guidance
May 2, 2017 4:02 PM EDTGilead Sciences (NASDAQ: GILD) reported Q1 EPS of $2.23, $0.05 worse than the analyst estimate of $2.28. Revenue for the quarter came in at $6.505 billion versus the consensus estimate of $6.62 billion.
Reiterates Full Year 2017 Guidance
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
... More